Alkem Laboratories is currently trading at Rs. 2955.00, up by 113.00 points or 3.98% from its previous closing of Rs. 2842.00 on the BSE.
The scrip opened at Rs. 2900.00 and has touched a high and low of Rs. 2972.60 and Rs. 2900.00 respectively. So far 4295 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 2975.65 on 04-Aug-2020 and a 52 week low of Rs. 1,682.10 on 07-Aug-2019.
Last one week high and low of the scrip stood at Rs. 2975.65 and Rs. 2538.20 respectively. The current market cap of the company is Rs. 33980.37 crore.
The promoters holding in the company stood at 62.43%, while Institutions and Non-Institutions held 15.52% and 21.80% respectively.
Alkem Laboratories has launched Favipiravir under the brand name ‘Alfluenza’ in India for the management of mild to moderate cases of COVID-19. Favipiravir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.
Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.